M2I-1_SDS_MedChemExpress

合集下载

科研神器医学实验报告

科研神器医学实验报告

实验名称:基于新型纳米药物递送系统的肿瘤靶向治疗研究实验目的:本研究旨在探索一种新型纳米药物递送系统在肿瘤靶向治疗中的应用,评估其治疗效果和安全性,为临床肿瘤治疗提供新的思路和方法。

实验材料:1. 实验细胞:人肺癌细胞系A549、人乳腺癌细胞系MCF-7、人正常肺上皮细胞系NCI-H292。

2. 实验药物:阿霉素(Adriamycin,ADM)。

3. 纳米药物递送系统:由聚乳酸-羟基乙酸共聚物(PLGA)和壳聚糖(CS)复合制备。

4. 实验试剂:DMEM培养基、胎牛血清、青霉素-链霉素溶液、MTT试剂盒、Annexin V-FITC/PI细胞凋亡检测试剂盒、实时荧光定量PCR试剂盒等。

5. 实验仪器:细胞培养箱、CO2培养箱、倒置显微镜、流式细胞仪、实时荧光定量PCR仪、酶标仪等。

实验方法:1. 纳米药物递送系统的制备:将PLGA和CS按照一定比例混合,加入溶剂中超声处理,制备成纳米药物载体。

将载体与ADM混合,采用旋转蒸发法去除溶剂,制备成纳米药物。

2. 细胞培养:将人肺癌细胞系A549、人乳腺癌细胞系MCF-7、人正常肺上皮细胞系NCI-H292分别接种于培养皿中,培养至对数生长期。

3. 药物处理:将A549和MCF-7细胞分为四组,分别为对照组(未处理)、ADM组(单独使用ADM)、纳米药物组(使用纳米药物)、纳米药物+ADM组(使用纳米药物和ADM的混合物)。

将细胞分别处理24小时后,进行以下实验。

4. MTT实验:检测各组细胞增殖情况,评估药物对肿瘤细胞的抑制作用。

5. 流式细胞术:检测各组细胞凋亡情况,评估药物对肿瘤细胞的杀伤作用。

6. Annexin V-FITC/PI细胞凋亡检测试剂盒:检测各组细胞凋亡率,进一步验证细胞凋亡情况。

7. 实时荧光定量PCR:检测各组细胞中凋亡相关基因的表达水平,如Bax、Bcl-2等。

8. 统计学分析:采用SPSS 22.0软件对实验数据进行统计分析,比较各组间差异。

低密度脂蛋白胆固醇测定试剂盒(直接法-表面活性剂清除法)产品技术要求meigaoyi

低密度脂蛋白胆固醇测定试剂盒(直接法-表面活性剂清除法)产品技术要求meigaoyi

低密度脂蛋白胆固醇测定试剂盒(直接法-表面活性剂清除法) 适用范围:用于体外定量检测人血清中低密度脂蛋白胆固醇的浓度。

1.1包装规格a) 试剂1:2×60ml,试剂2:2×20ml;b) 试剂1:4×60ml,试剂2:4×20ml;c) 试剂1:3×60ml,试剂2:3×20ml;d) 试剂1:2×45ml,试剂2:2×15ml;e)试剂1:1×45ml,试剂2:1×15ml;f)试剂1:2×16.8ml,试剂2:2×5.6ml;g)试剂1:2×300ml,试剂2:2×100ml。

1.2主要组成成分试剂1主要组成成分试剂2主要组成成分2.1 外观和性状2.1.1 试剂盒各组分应齐全、完整、液体无渗漏;外包装完好、无破损,标签完好、字迹清晰。

2.1.2 试剂1应为无色透明溶液;试剂2应为淡黄色透明溶液。

2.2 净含量应不低于试剂瓶标示装量。

2.3 试剂空白吸光度测定试剂空白吸光度,应<0.05。

2.4 分析灵敏度测试1.0mmol/L样本时,吸光度变化(ΔA)应大于0.03。

2.5 准确度测定值与靶值相对偏差不超过±10%。

2.6 精密度2.6.1重复性重复测试正常浓度和高浓度样本,变异系数(CV)应不大于3%。

2.6.2批间差抽取3个不同批号试剂,对同一浓度样品进行重复检测,批间相对极差应不大于10%。

2.7 线性试剂线性在(0.02,11.6)mmol/l范围内,2.7.1 线性回归的相关系数(r)应不低于0.995;2.7.2(0.02,3.00]mmol/l区间内,绝对偏差不超过±0.3mmol/L;2.7.3(3.00,11.6)mmol/l区间内,相对偏差不超过±10%。

2.8 稳定性该产品在2℃~8℃条件下贮存有效期为18个月,取效期末的产品进行检测,应符合2.1、2.3、2.4、2.5、2.6.1、2.7之规定。

Gelucire-14-44-SDS-MedChemExpress

Gelucire-14-44-SDS-MedChemExpress

Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Nov.-23-2018Print Date:Nov.-23-20181. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :Gelucire 14/44Catalog No. :HY-Y1892CAS No. :121548-04-71.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:NoneFormula:N/AMolecular Weight:N/ACAS No. :121548-04-74. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Pure form-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Oil)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2018 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

SDS增敏荧光光度法测定人血清中左氧氟沙星的残留量

SDS增敏荧光光度法测定人血清中左氧氟沙星的残留量

SDS增敏荧光光度法测定人血清中左氧氟沙星的残留量
董学芝;席会平;胡卫平;李畅;张国胜
【期刊名称】《华西药学杂志》
【年(卷),期】2007(22)4
【摘要】目的建立人血清中左氧氟沙星(LOX)残留量的快速测定方法。

方法采用十二烷基硫酸钠(SDS)增敏荧光光度法。

结果用无水乙醇沉淀蛋白,对血清进行预处理,利用LOX-SDS体系测定,人血清中LOX在0.1~5.0μg.ml-1时,荧光强度与浓度呈线性关系,其回归方程为:F=5.552+40.019C(r=0.9990),平均回收率为
99.72%,RSD=0.68%。

结论所建方法简便、准确、快速,可用于人血清中LOX的测定。

【总页数】3页(P435-437)
【关键词】十二烷基硫酸钠增敏荧光分光光度法;左氧氟沙星;血清;残留量
【作者】董学芝;席会平;胡卫平;李畅;张国胜
【作者单位】河南大学化学化工学院
【正文语种】中文
【中图分类】R917
【相关文献】
1.CTMAB增敏荧光光度法测定牛奶中莫西沙星残留量 [J], 蔡花真;董贺;席会平;龚文琪
2.聚乙二醇辛基苯基醚胶束增敏荧光分光光度法测定人尿中痕量1-羟基芘 [J], 欧
阳运富;王永生;唐宏兵
3.微乳液增敏对硝基苯基荧光酮光度法测定人发中痕量镍 [J], 杜斌;吴丹;魏琴;张慧;欧庆瑜
4.功能性CdS纳米荧光探针荧光增敏法测定人血清白蛋白 [J], 汪乐余;周运友;朱昌青;张明翠;陶海升;王伦
5.新荧光试剂5-(4-羧基苯偶氮)-8-水杨醛缩氨基喹啉荧光增敏法测定人血清蛋白质 [J], 张明翠;汪乐余;李玲;陈红旗;张德兴;王伦
因版权原因,仅展示原文概要,查看原文内容请购买。

美国Medchemexpress化合物库(小分子库)_Medchemexpress_(MCE中国)

美国Medchemexpress化合物库(小分子库)_Medchemexpress_(MCE中国)

美国Medchemexpress化合物库(小分子库)-原装进口,现货供
应,提供组合定制服务
品牌:Medchemexpress (MCE)
保存条件:-20℃
供应商:MCE中国
数量:大量
保质期:2年
Size:
Pre-dissolved DMSO/Solid(Or dry solid)
100 uL/well (10 mM solution)
200 uL/well (10 mM solution)
MedChemExpress (MCE)专注于各种抑制剂、调节剂、API、天然产物及化合物库,总部位于美国新泽西。

MCE经过十年努力已成为全球生物活性小分子领域的一流供应商。

MedChemExpress(MCE)产品涵盖近20个热门研究领域,1000多个细分靶点,超过3000个现货抑制剂、拮抗剂和激动剂。

相关的应用成果已发表于Nature、Cell等国际知名杂志,在全球20余个国家地区设有代理机构。

上海皓元生物医药科技有限公司(MCE 中国) 是MedChemExpress (MCE) 亚洲总代理。

MCE化合物库涵盖20余种不同的类型,超过2500个化合物,进口原装,
现货供应,提供详实的生物活性信息、化学结构信息、质控图谱(NMR和HPLC 等)。

还可根据您的实际研究需要,为您度身定制任意组合、规格、布板的特殊化合物库。

/screening-libraries.html
现有特色化合物库有:。

艾滋病确证实验流程

艾滋病确证实验流程

艾滋病确证实验原理:新加坡MP 生物医学亚太有限公司生产的HIV-1+2 抗体免疫印迹试剂(HIVBLOT 2.2) 1)原理WB 是将HIV 蛋白经SDS-PAGE,由于蛋白分子大小不同而分离开来,然后再把这些已分离的不同蛋白带转移到硝化纤维膜上,以后用不同的方式,包括非常敏感的免疫酶法,检测HIV 抗体。

每一条硝化纤维膜上均含有经电泳分离过的HIV 抗原。

若有相应抗体就会与硝化纤维膜条上的抗原带相结合。

然后与抗人的IgG 酶结合物反应。

在底物作用下,硝化纤维膜条带上呈现紫色,表示阳性反应。

步骤:基本检测程序(1)准备试剂:配制稀释洗涤液、印迹缓冲液、工作酶结合溶液。

(2)湿润膜条:用镊子从塑料管中小心取出所需的硝化纤维膜条,其中包括 3 条对照(强阳性、弱阳性、阴性对照各 1 条),并且将有编号的膜面向上放入分析槽中,随后加人 2 ml 已经稀释好的洗液,室温(22~28℃)振荡浸泡至少5 min,然后吸干槽内液体。

(3)加样:每槽中加入2 ml 印迹缓冲液和20ul 待检标本或对照(4)孵育:盖上盖子,室温振荡1 h(也可采用室温振荡16~18 h)。

(5)洗涤:小心打开盖子,吸干槽内液体,避免标本交叉污染。

加入2 ml 已经稀释的洗涤液,室温浸泡振荡5 min,再吸干槽内液体。

如此反复洗涤3 次。

(6)酶结合:加入2 ml 工作酶结合溶液,盖上盖子,室温振荡1 h(如果在6 步骤中采用室温振荡16~18 h 的,则此步酶反应步骤中室温振荡30 min)。

(7)洗涤:吸干槽内液体,再洗涤3 次。

(8)显色:加入2 ml 底物溶液,室温振荡15 min。

(9)终止:吸干槽内液体,加入蒸馏水终止反应,反复3 次,随后用镊子小心取出膜片于滤纸巾上,并开始读膜片结果。

(10)结果判定标准:每次实验须设立对照血清,如阳性对照必须全部条谱带均出现;弱阳性对照可以谱带不全,但必须够判定阳性的结果;阴性对照则无反应谱带。

Western Blot及IP细胞裂解液

Western Blot及IP细胞裂解液
8. Cheng BQ, Gong W, Geng Y, Chen L, Wu JB, Jiang B. Study of r elationship between expr ession of galectin- 3 and malignant degr ee of color ectal cancer in differ ential pathologic stage. China Journal of Modern Medicine. Jul.2007;Vol.17 No.13.
用Western及IP细胞裂解液裂解得到的蛋白样品,可以用碧云天生产的BCA蛋白浓度测定试剂盒(P0009/P0010/P0010S/ P0011/P0012/P0012S)测定蛋白浓度。由于含有较高浓度的Triton X-100等干扰物质,不能用Bradford法测定由本裂解液裂 解得到样品的蛋白浓度。
孔板每孔加入100-200微升裂解液的比例加入裂解液。用枪吹打数下,使裂解液和细胞充分接触。通常裂解液接触细胞1-2 秒后,细胞就会被裂解。 对于悬浮细胞:离心收集细胞,用手指把细胞用力弹散。按照6孔板每孔细胞加入100-200微升裂解液的比例加入裂解 液。再用手指轻弹以充分裂解细胞。充分裂解后应没有明显的细胞沉淀。如果细胞量较多,必需分装成50-100万细胞/ 管,然后再裂解。大团的细胞较难裂解充分,而少量的细胞由于裂解液容易和细胞充分接触,相对比较容易裂解充分。 3. 充分裂解后,10000-14000g离心3-5分钟,取上清,即可进行后续的PAGE、Western、免疫沉淀和免疫共沉淀等操作。 裂解液用量说明:通常6孔板每孔细胞加入100微升裂解液已经足够,但如果细胞密度非常高可以适当加大裂解液的用量 到150微升或200微升。 对于组织样品: 1. 把组织剪切成细小的碎片。 2. 融解Western及IP细胞裂解液,混匀。取适当量的裂解液,在使用前数分钟内加入PMSF,使PMSF的最终浓度为1mM。 3. 按照每20毫克组织加入100-200微升裂解液的比例加入裂解液。(如果裂解不充分可以适当添加更多的裂解液,如果需要高 浓度的蛋白样品,可以适当减少裂解液的用量。) 4. 用玻璃匀浆器匀浆,直至充分裂解。 5. 充分裂解后,10000-14000g离心3-5分钟,取上清,即可进行后续的PAGE、Western、免疫沉淀和免疫共沉淀等操作。 6. 如果组织样品本身非常细小,可以适当剪切后直接加入裂解液裂解,通过强烈vortex使样品裂解充分。然后同样离心取上

稳态荧光探针法测定SDS表面活性剂胶束聚集数

稳态荧光探针法测定SDS表面活性剂胶束聚集数

稳态荧光探针法测定SDS表面活性剂胶束聚集数
陈红梅
【期刊名称】《广东化工》
【年(卷),期】2009(36)8
【摘要】以芘作为荧光探针,十六烷基氯化吡啶(CPC)作为猝灭剂,根据芘的荧光强度之比随表面活性剂水溶液浓度的变化,测定十二烷基硫酸钠(SDS)的临界胶束浓度(cmc),测定值与文献值较一致.并用外推法得到SDS的胶束聚集数(n).文章提供了一种简单可行的实验方法了来计算和评价胶束的基本特性.
【总页数】2页(P219-220)
【作者】陈红梅
【作者单位】武汉工业学院,化学与环境工程系,湖北,武汉,430023
【正文语种】中文
【中图分类】O65
【相关文献】
1.稳态荧光探针法研究槐糖脂生物表面活性剂的胶束化行为 [J], 宋丹丹;梁生康;王江涛;王修林
2.稳态荧光探针法测定三聚季铵盐表面活性剂的胶束聚集数 [J], 李新宝;徐丽;孟校威;韩智慧;雒廷亮;刘国际
3.稳态荧光探针法测定临界胶束聚集数 [J], 方云;刘雪锋;夏咏梅;杨扬;蔡琨;徐廷穆;赵宪英
4.稳态荧光探针法测定松香基季铵盐Gemini表面活性剂胶束聚集数 [J], 蒋福宾;
曾华辉;杨正业;李俊杰;宋宝玲
5.一类新的表面活性剂——长链烷基三苯基鏻——Ⅵ.稳态荧光猝灭法测定十二烷基三苯基溴化鏻胶束的平均簇集数 [J], 江云宝;许金钩;陈国珍
因版权原因,仅展示原文概要,查看原文内容请购买。

  1. 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
  2. 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
  3. 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。

Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:May-24-2017Print Date:May-24-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :M2I-1Catalog No. :HY-100341CAS No. :312271-03-71.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:NoneFormula:C19H24N4O4SMolecular Weight:404.48CAS No. :312271-03-74. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance Off-white to orange (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

相关文档
最新文档